Biomarker Applications in Diagnostics of Fungal Infections

[1]  W. Melchers,et al.  Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model , 2016, Journal of Clinical Microbiology.

[2]  J. Donnelly,et al.  How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation , 2016, British journal of haematology.

[3]  J. Pardo,et al.  Clinical validity of bis(methylthio)gliotoxin for the diagnosis of invasive aspergillosis , 2015, Applied Microbiology and Biotechnology.

[4]  G. Driessen,et al.  Diagnostic Performance of Galactomannan Antigen Testing in Cerebrospinal Fluid , 2015, Journal of Clinical Microbiology.

[5]  P. Neumeister,et al.  Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test. , 2015, International journal of antimicrobial agents.

[6]  J. Maertens,et al.  Role of Non-Culture-Based Tests, with an Emphasis on Galactomannan Testing for the Diagnosis of Invasive Aspergillosis , 2015, Seminars in Respiratory and Critical Care Medicine.

[7]  F. Wang,et al.  A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-D-glucan for invasive fungal infection: Focus on cutoff levels. , 2015, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[8]  T. Anagnostou,et al.  Galactomannan and Polymerase Chain Reaction-Based Screening for Invasive Aspergillosis Among High-Risk Hematology Patients: A Diagnostic Meta-analysis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Tieying Hou,et al.  The Screening Performance of Serum 1,3-Beta-D-Glucan in Patients with Invasive Fungal Diseases: A Meta-Analysis of Prospective Cohort Studies , 2015, PloS one.

[10]  Jianying Zhou,et al.  Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis. , 2015, Journal of medical microbiology.

[11]  J. Wingard,et al.  Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  N. Shire,et al.  Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis , 2015, PloS one.

[13]  W. Melchers,et al.  Analytical Comparison of In Vitro-Spiked Human Serum and Plasma for PCR-Based Detection of Aspergillus fumigatus DNA: a Study by the European Aspergillus PCR Initiative , 2015, Journal of Clinical Microbiology.

[14]  W. Melchers,et al.  Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative , 2015, Journal of Clinical Microbiology.

[15]  C. Solano,et al.  Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  J. Wingard,et al.  Combination Antifungal Therapy for Invasive Aspergillosis , 2015, Annals of Internal Medicine.

[17]  J. Rello,et al.  Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes , 2015, Critical Care.

[18]  R. Nation,et al.  Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: A systematic review and meta-analysis , 2015, Critical reviews in microbiology.

[19]  E. Anaissie,et al.  How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. , 2014, Blood.

[20]  M. Cuenca‐Estrella,et al.  Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Comolli,et al.  A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. Caliendo,et al.  PCR in Diagnosis of Invasive Aspergillosis: a Meta-Analysis of Diagnostic Performance , 2014, Journal of Clinical Microbiology.

[23]  E. Anaissie,et al.  Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome , 2013, Haematologica.

[24]  T. Hohl,et al.  The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  P. White,et al.  Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway. , 2013, The Journal of infection.

[26]  John Moore,et al.  Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. , 2013, The Lancet. Infectious diseases.

[27]  A. Caliendo,et al.  Development and Evaluation of a Calibrator Material for Nucleic Acid-Based Assays for Diagnosing Aspergillosis , 2013, Journal of Clinical Microbiology.

[28]  Peter J. Sterk,et al.  Electronic Nose Technology for Detection of Invasive Pulmonary Aspergillosis in Prolonged Chemotherapy-Induced Neutropenia: a Proof-of-Principle Study , 2013, Journal of Clinical Microbiology.

[29]  R. Barton.  Laboratory Diagnosis of Invasive Aspergillosis: From Diagnosis to Prediction of Outcome , 2013, Scientifica.

[30]  R. Herbrecht,et al.  Risk stratification for invasive aspergillosis in immunocompromised patients , 2012, Annals of the New York Academy of Sciences.

[31]  Lizhang Chen,et al.  Systematic Review and Meta-Analysis of Detecting Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosing Invasive Aspergillosis , 2012, PloS one.

[32]  C. Heussel,et al.  ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia , 2012, Bone Marrow Transplantation.

[33]  C. Viscoli,et al.  ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients , 2012, Bone Marrow Transplantation.

[34]  M. Netea,et al.  Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis , 2012, Journal of Clinical Microbiology.

[35]  J. Meis,et al.  Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis. , 2012, Diagnostic microbiology and infectious disease.

[36]  B. Fuchs,et al.  Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  C. Thornton,et al.  Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology , 2012, Journal of visualized experiments : JoVE.

[38]  O. Lortholary,et al.  β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Cisneros,et al.  Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach , 2012, Haematologica.

[40]  K. Theunissen,et al.  Detection of Galactomannan in Bronchoalveolar Lavage Fluid Samples of Patients at Risk for Invasive Pulmonary Aspergillosis: Analytical and Clinical Validity , 2012, Journal of Clinical Microbiology.

[41]  J. Mandrekar,et al.  Detection of (1, 3)-β-d-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts , 2012, Mycopathologia.

[42]  W. Melchers,et al.  Evaluation of Aspergillus PCR Protocols for Testing Serum Specimens , 2011, Journal of Clinical Microbiology.

[43]  M. Falagas,et al.  β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  Ke Wang,et al.  Diagnosis of invasive fungal disease using serum (1→3)-β-D-glucan: a bivariate meta-analysis. , 2011, Internal medicine.

[45]  Jin-liang Kong,et al.  Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. , 2010, Chest.

[46]  W. Melchers,et al.  Specimens in Whole-Blood Aspergillus fumigatus Critical Stages of Extracting DNA from , 2014 .

[47]  T. Peláez,et al.  Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[48]  A. De Luca,et al.  Dynamics of extracellular release of Aspergillus fumigatus DNA and galactomannan during growth in blood and serum. , 2010, Journal of medical microbiology.

[49]  J. Donnelly,et al.  Galactomannan detection and diagnosis of invasive aspergillosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  S. Koo,et al.  Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis , 2010, Journal of Clinical Microbiology.

[51]  W. Melchers,et al.  Aspergillus PCR: One Step Closer to Standardization , 2010, Journal of Clinical Microbiology.

[52]  J. Loeffler,et al.  Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.

[53]  G. Verhoef,et al.  Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients , 2009, Cancer.

[54]  D. Kontoyiannis,et al.  Invasive aspergillosis in glucocorticoid-treated patients. , 2009, Medical mycology.

[55]  B. Healy,et al.  Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients , 2008, Journal of Clinical Pathology.

[56]  K. Theunissen,et al.  Early diagnosis and preemptive therapy of pulmonary mold infections in high-risk patients , 2008, Current infectious disease reports.

[57]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  C. Thornton.  Development of an Immunochromatographic Lateral-Flow Device for Rapid Serodiagnosis of Invasive Aspergillosis , 2008, Clinical and Vaccine Immunology.

[59]  J. Sinko,et al.  Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy‐driven survey , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[60]  E. Anaissie,et al.  Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[61]  W. Meersseman,et al.  Invasive aspergillosis in the ICU: an emerging disease , 2007, Intensive Care Medicine.

[62]  V. Rickerts,et al.  Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  A. Francesconi,et al.  Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. , 2007, The Journal of infectious diseases.

[64]  B. D. de Pauw,et al.  Prophylaxis and aspergillosis--has the principle been proven? , 2007, The New England journal of medicine.

[65]  J. Fine,et al.  Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  D. Kontoyiannis,et al.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.

[67]  W. Leisenring,et al.  Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  T. Peláez,et al.  Workload Due to Aspergillus fumigatus and Significance of the Organism in the Microbiology Laboratory of a General Hospital , 2005, Journal of Clinical Microbiology.

[69]  S. Balajee,et al.  Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. , 2004, The Journal of infectious diseases.

[70]  J. Donnelly,et al.  Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. , 2004, The Lancet. Infectious diseases.